Spots Global Cancer Trial Database for Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
Official Title: Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL
Study ID: NCT01809600
Interventions
Study Description
Brief Summary: This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.
Detailed Description: Inclusion criteria 1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria 2. age \>20 yrs 3. received rituximab+chemotherapy as first-line treatment 4. with measurable or evaluable lesion 5. with complete set of clinical and laboratory data for the analysis
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Gachon University Gil Medical Center, Incheon, , Korea, Republic of
Contact Details
Name: Suk Jin Kim, MD, PhD
Affiliation: Samsung Medical Center, Seoul, Korea
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
